RxDoctor Payments Data

Cindy McAdams, DO

Family Medicine · Madison, ALNPI 1306829759

Payments from drug & device makers

$3,760in general payments, 2019–2025

Across 224 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$825
  • Lilly USA, LLC$428
  • Merck$244
  • Amgen$222
  • Astellas Pharma US Inc$204
  • AstraZeneca$199
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$3,68998%
  • Education$712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,760 in reported general payments places this provider in the 75th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$85,189
Medicare patients
258
Services billed
919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$65,870
EliquisApixaban44$44,526
JardianceEmpagliflozin19$25,814
FarxigaDapagliflozin Propanediol21$17,707
TrulicityDulaglutide12$13,993
Repatha SureclickEvolocumab15$12,919
Synjardy XrEmpagliflozin/Metformin Hcl12$7,598
SynthroidLevothyroxine Sodium48$4,590
Levothyroxine Sodium334$4,443
Sumatriptan Succinate35$3,201
Atorvastatin Calcium232$3,010
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,912
Rosuvastatin Calcium136$2,693
Metoprolol Succinate129$2,498
Bupropion XlBupropion Hcl47$2,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$825$65,87053 claims
PfizerEliquis$172$44,52644 claims
Boehringer IngelheimJardiance, Synjardy Xr$159$33,41231 claims
AstraZenecaFarxiga$199$17,70721 claims
Lilly USA, LLCTrulicity$428$13,99312 claims
AbbVieSynthroid$170$4,59048 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Madison

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →